3rd Quarter - Report

NOVO NORDISK INC. for NOVO NORDISK INC.

Firm
Client
Income
—
Expenses
$400,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Trans-Pacific Partnership (TPP): biosimilar provisions

Contacted: HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); Centers For Disease Control & Prevention (CDC); SENATE; Centers For Medicare and Medicaid Services (CMS); Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); White House Office; Labor, Dept of (DOL)

Taxation/Internal Revenue Code TAX

H.R. 436 Protect Medical Innovation Act of 2011

Contacted: Labor, Dept of (DOL); Health & Human Services, Dept of (HHS); White House Office; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Centers For Disease Control & Prevention (CDC); Natl Institutes of Health (NIH); Food & Drug Administration (FDA); SENATE; Executive Office of the President (EOP)

Bills named: H.R. 436 (112th)

Health Issues HCR

Supporting increasing funding opportunities for better care and treatment of people with diabetes in P.L. 111-148, Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152, The Health Care & Education Affordability Reconciliation Act of 2010: Issues related to diabetes generally, and specifically minority health, diabetes screening, National Diabetes Prevention Program, Special Diabetes Program reauthorization, National Prevention Strategy, Medicaid Quality Measures, Medicare Annual Wellness Visit, ACOs (related to Medicare Share Savings Program), Coverage of Preventive Services under ACA, HHS Strategic Plan, HHS Multiple Chronic Conditions Framework, National Quality Strategy, Prevention and Public Health Fund, Diabetes Prevention Issues in a Survey of Primary Care Physicians, Adequate Inclusion of Diabetes Care in the Essential Health Benefits Package, IOM Committee on Valuing Community-Based Non-Clinical Prevention Policies and Wellness Strategies, DOL Survey of Employer-Sponsored Health Insurance Coverage, CDC National Survey of Primary Care Policies for Managing Patients with Higher Blood Pressure, High Cholesterol, or Diabetes (NSPCP); H.R. 2954, the Health Equity and Accountability Act of 2011; HR 2960 National Diabetes Clinical Care Commission Act; S. 1559 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act FY2012 on National Diabetes Prevention Program; CMS Obesity Intervention; Healthy People 2020 Abstract; CMS CLIA Program & HIPAA Privacy Rule Patient Access to Test Reports; AHRQ regarding the USPSTF recommendation on screening and management of obesity in adults; PCORI Draft Research Agenda

Contacted: Health & Human Services, Dept of (HHS); Natl Institutes of Health (NIH); White House Office; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Labor, Dept of (DOL); SENATE; Centers For Disease Control & Prevention (CDC); Executive Office of the President (EOP)

Bills named: H.R. 2960 (112th), S. 1559 (112th), H.R. 2954 (112th)

Medicare/Medicaid MMM

P.L. 111-148, Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152, The Health Care & Education Affordability Reconciliation Act of 2010; CMS Proposed Coverage Decision Memorandum for Intensive Behavioral Therapy for Obesity; Medicare Diabetes Screening; HR 6548 Medicare Diabetes Prevention Act of 2012; S 3463 Medicare Diabetes Prevention Act of 2012; HR 2741, Preventing Diabetes in Medicare Act of 2011 and Prediabetes generally; Medicaid coverage of obesity counseling and expanding provider type; Issues related to Medicare Part D and Medicaid rebates as contained in P.L. 112-25 Budget Control Act of 2011 (deficit reduction)

Contacted: Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); White House Office; SENATE; Labor, Dept of (DOL); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Centers For Disease Control & Prevention (CDC)

Bills named: H.R. 2741 (112th), H.R. 6548 (112th)

Budget/Appropriations BUD

S. 3295 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act FY2013 (National Diabetes Prevention Program); HR 6482 The Preventative Health Savings Act of 2012 (modernizing cost estimates with respect to CBO scoring of preventive health legislation); and National Diabetes Prevention Program

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Natl Institutes of Health (NIH); White House Office; Centers For Disease Control & Prevention (CDC); SENATE; Labor, Dept of (DOL); Executive Office of the President (EOP)

Bills named: S. 3295 (112th), H.R. 6482 (112th)

Pharmacy PHA

P.L. 111-148, Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152, The Health Care & Education Affordability Reconciliation Act of 2010: Issues regarding comparative effectiveness, implementation of Physician Payment Sunshine provisions and Prescription Drug Sample reporting provisions; S.3187 FDA Safety and Innovation Act; H.R. 4274 Best Pharmaceuticals for Children Act/Pediatric Research Exclusivity Act; H.R. 3026 Safeguarding America's Pharmaceuticals Act of 2011; Pharmaceutical Traceability Enhancement Code (Rx TEC) Act; H.R. 5973 FY2013 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (FDA funding); 340B

Contacted: Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); White House Office; Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC); Labor, Dept of (DOL); Natl Institutes of Health (NIH)

Bills named: H.R. 3026 (112th), S. 3187 (112th), H.R. 4274 (112th), H.R. 5973 (112th)

Law Enforcement/Crime/Criminal Justice LAW

S. 1002 SAFE DOSES Act and HR 4223 Safe Doses Act (Modernizing criminal laws concerning theft of medical products)

Contacted: Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); White House Office; Labor, Dept of (DOL); Health & Human Services, Dept of (HHS); Natl Institutes of Health (NIH); SENATE; HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); Centers For Disease Control & Prevention (CDC)

Bills named: H.R. 4223 (112th), S. 1002 (112th)

Foreign entities

Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.

EntityCountryPrincipal place of businessOwnershipContribution declared
NOVO NORDISK FONDEN (FOUNDATION) Denmark Denmark 25.5% —
NOVO NORDISK A/S Denmark Denmark 100.0% —
NOVO A/S Denmark Denmark 25.5% —

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.